Axogen, Inc.

218 articles about Axogen, Inc.

• Axogen to Participate at JMP Securities Life Sciences Conference

  5/12/2023

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter Mariani, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York on Monday, May 15, 2023 at 3:00 p.m. ET.

• Axogen, Inc. Reports 2023 First Quarter Financial Results

  5/9/2023

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the first quarter ended March 31, 2023.

• Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

  4/18/2023

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens.

• Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results

  3/14/2023

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022.

• Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel

  3/6/2023

  Axogen, Inc. today announced the appointment of Marc Began as Executive Vice President.

• Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023

  3/2/2023

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2023 before the market opens.

• Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

  1/9/2023

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2022 revenue.

• Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits

  1/5/2023

  Axogen, Inc. announced the independent publication of a comprehensive, retrospective clinical review comparing the meaningful recovery rates between allograft, autograft, and conduits using a meta-analysis methodology.

• Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference

  1/4/2023

  Axogen, Inc. today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan 41st Annual Healthcare Conference in San Francisco.

• Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation

  12/19/2022

  Axogen, Inc. announced that Bri Majsiak, a Resensation® patient, has been selected to ride on the 2023 Donate Life Rose Parade Float and Madelyn Nicpon will be honored at this year’s event through a floragraph that will adorn the float.

• Axogen, Inc Reports 2022 Third Quarter Financial Results

  11/8/2022

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2022.

• Axogen to Participate at Upcoming Investor Conferences - November 03, 2022

  11/3/2022

  Axogen, Inc. announced that Karen Zaderej, chairman, CEO, and president, and Peter Mariani, executive vice president and CFO will participate in upcoming investor conferences in November and December.

• Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.

  10/31/2022

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that effective December 13, 2022, Adrian Tyndall, M.D., MPH, FACEP has been appointed as an independent member to the company’s board of directors and will serve on the Quality, Compliance, and Portfolio Management Committee.

• Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022

  10/20/2022

  Axogen, Inc. today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022 before the market opens.

• Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand

  9/22/2022

  Axogen, Inc. announced that it will participate in the 77th Annual Meeting of the American Society for Surgery of the Hand (ASSH) being held in Boston from September 29-October 1, 2022.

• Axogen, Inc Reports 2022 Second Quarter Financial Results

  8/3/2022

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the second quarter ended June 30, 2022.

• Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance

  7/18/2022

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced organizational updates and preliminary second quarter revenue.

• 

  Why Now is the Best Time to Make the Switch to Pharma and Biotech

  7/7/2022

  BioSpace sat down with Axogen's Chief Human Resources Officer Maria Martinez to understand why now is the best time to make the switch to pharma and biotech.
• 

  Life Sciences Industry Emphasizes Growth, Purpose in Fight for Talent

  7/5/2022

  According to a recent BioSpace report, the top three motivators for employees to look for a new job are growth opportunities, greater compensation and the desire for a new challenge.

• Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft

  5/4/2022

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injuries.